Contineum Therapeutics, Inc. CTNM
At closeNov 5, 2026, 8:51 AM EST
Pre-market · Nov 5, 8:51 AM ET
- YTD
- -14.35%
- 1 year
- -6.23%
- Market cap
- 384.41M
- EPS (ttm)
- -1.77
- Shares out
- 19.05M
- Forward P/E
- -7.68
- YTD return
- -14.35%
- 1-year return
- -6.23%
- Volume
- 804.45K
- Avg volume
- 845.39K
- Open
- 10.00
- Previous close
- 9.79
- Day's range
- 9.56 – 10.32
- 52-week range
- 6.73 – 17.79
- Price target
- 29.25 (+198.8%)
- Earnings date
- Feb 5, 2025
6M -4.60 (-31.97%)
Key statistics
- Enterprise value
- 134.70M
- PEG ratio
- 0.00
- Price / book
- 1.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -22.27M
- Total cash
- 213.91M
- Total debt
- 611.00K
- Return on equity
- -20.76%
- Short % of float
- 0.00%
- 50-day average
- 15.77
- 200-day average
- 17.15
Analyst view
- Target (low)
- 25.00
- Target (mean)
- 29.25
- Target (high)
- 32.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 5, 2025
Expected Feb 5, 2025. Consensus EPS estimate -0.435.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2025 | Dec 1, 2024 | -0.44 | — | — | — |
| Nov 6, 2024 | Sep 1, 2024 | -0.41 | -0.40 | +0.01 | +2.44% |
| Aug 13, 2024 | Jun 1, 2024 | -0.37 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.37 | -0.39 | -0.02 | -5.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 22, 2024 | Baird | init | — | Outperform |
| Aug 14, 2024 | RBC Capital | main | Outperform | Outperform |
| Apr 30, 2024 | RBC Capital | init | — | Outperform |
| Apr 30, 2024 | Stifel | init | — | Buy |
| Apr 30, 2024 | Morgan Stanley | init | — | Overweight |
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- contineum-tx.com
News
Contineum Therapeutics Q3 EPS $(0.49) Misses $(0.45) Estimate 
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results 
Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30 
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14 
12 Health Care Stocks Moving In Monday's Intraday Session 
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy 
Why Is Contineum Therapeutics Stock Falling Monday? 
Why Is Contineum Therapeutics Stock Falling Monday? - 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on CTNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUHN STEPHEN L | Officer | Conversion of Exercise of derivative security | Aug 12, 2024 | 12,800 |
| LORRAIN DANIEL S. PH.D. | Officer | Sale | Nov 24, 2024 | 172,460 |
| VERSANT VENTURE CAPITAL VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 8, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Johnson & Johnson | 10.39% | 1,979,173 | 27.99M | Sep 29, 2024 |
| Suvretta Capital Management, LLC | 9.03% | 1,720,000 | 24.32M | Sep 29, 2024 |
| Perceptive Advisors Llc | 7.96% | 1,516,668 | 21.45M | Sep 29, 2024 |
| Franklin Resources, Inc. | 7.60% | 1,447,550 | 20.47M | Sep 29, 2024 |
| Versant Venture Management, LLC | 4.82% | 918,163 | 12.98M | Sep 29, 2024 |
| Sectoral Asset Management, Inc. | 4.20% | 800,887 | 11.32M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.69% | 512,025 | 7.24M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.57% | 299,583 | 4.24M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 1.39% | 264,800 | 3.74M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.05% | 200,000 | 2.83M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 0.75% | 142,871 | 2.02M | Oct 30, 2024 |
| Fidelity Advisor Health Care Fund | 0.67% | 128,000 | 1.81M | Oct 30, 2024 |